her1/egfr and her2/erbb2 pathways o. segatto, regina elena cancer institute
TRANSCRIPT
RTK activity regulates cellular programmes crucial to cell transformation and tumour progression
The hallmarks of cancer
RTKs have intrinsic tyrosinekinase activity which is activated
upon ligand binding
RTKs are bistable systems, i.e. they transit from an “off” to an
“on” state with no intermediate states
Kinase domain
Extracellular domain
COOH tail
Ligand binding induces kinase activation and receptor self-phosphorylation on specific Tyr residues
Specific p-Tyr sites generated by RTK autophosphorylationinitiate downstream signalling by acting as docking sites
for cellular proteins containing SH2 or PTB domains.
All SH2 and some PTB domains bind to p-Tyr. Specificity of molecular recognition is dictated by residues C-terminal
to p-Tyr for SH2 domains and N-terminal to p-Tyr for PTB domains.
The human genome encodes 139 SH2-containing and 49 PTB-containing proteins.
EGFR
PLC-
IP3 + DAG
Activation of downstream signalling: enzymes containing an SH2 domain bind to pY-EGFR and are relocated to the cell surface
Relocation onto the EGFR allows PLC- to be activated via Tyr phosphorilation and “induced proximity”
PIP2
RAS
EGFR
PI-3K-AKTRAF-ERKSOSGRB2
Activation of downstream signalling: SH2 adaptors bind to pY-EGFR and relocate enzymes to the cell surface
RAS
GTP (active)
GDP (inactive)
Formazione del “signalosoma” su RTK: perché?
Concentrazione di effettori enzimatici in membrana
Attivazione rapida e reversibile di funzioni enzimatiche
Attivazione integrata di vie di segnalazione multiple
Amplificazione del segnale
Polarizzazione del segnale
RTK activation needs to be tightly controlled
Aberrant RTK activity is linked to cell transformation
Focus
Understanding the “design principles” of ErbBactivation, as deviation from these design principlesmay underline oncogenic conversion of ErbB RTKs
Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding
Restricted ligand availability limits receptor activation
Feedback inhibition restricts receptor activity
Key design principles
a) on-demand-only activationb) prevention of unwanted activationc) tight monitoring of receptor activity
Operational principles
Intramolecular interactions lock EGF receptors in a monomeric inactive conformation, which is released upon ligand binding
Part 1: structural transitions in the extracellular domain
Xuewu Zhang et al., Cell, Volume 125, Issue 6, 1137-1149, 13 June 2006
Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding
Part 2: structural transitions in the catalytic domain
Ligand-induced EGFR dimerizationreleases the intra-molecular inhibitionof EGFR kinase via inter-molecularallosteric activation
• Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding
• Restricted ligand availability limits receptor activation
• Feedback inhibition restricts receptor activity
Operational principles
Restricted ligand availability limits receptor activation
ErbB ligands are synthesised by stromal cells as membrane-bound precursors. Cleavage by proteases releases the soluble form
• Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding
• Restricted ligand availability limits receptor activation
• Feedback inhibition restricts receptor activity
Operational principles
Downregulation depletes receptors and ligands, leading to cellular refractoriness to further homologous stimulation
Inducible feedback regulators?
Feedback inhibition restricts receptor activity
MIG6 is an inducible feedback inhibitor that suppresses EGFR catalytic activation by binding to a dimer interface located in the COOH lobe of the EGFR kinase domain
Xuewu Zhang, Kerry A. Pickin, Ron Bose, Natalia Jura, Philip A. Cole & John KuriyanNature 450, 741-744(29 November 2007)
EGFR signalling activity is the result of a dynamicequilibrium between mechanisms of signal
generation and signal extinction
RTKs are bistable systems, i.e. they transit from an “off” to an
“on” state with no intermediate states
Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding
Restricted ligand availability limits receptor activation
Feedback inhibition restricts receptor activity
Oncogenic conversion of EGFR and ERBB2 releases the receptors from these constrains, thus allowing unabated signalling activity
ErbB receptors at work: the network context
Thomas Jefferson, United States Declaration of Independence, 1776
… whereas ErbB receptors, ligands and ligand-receptor combinations are not!
Some ligands do not lead to EGFR degradation: TGF and Epiregulin drive complete and fast EGFR recycling, Amphiregulin drives both fast and slow EGFR recycling.
These ligands may be continuously re-used by the cell and also allow the EGFR to escape down-regulation.
High gain of signalling potency
ErbB2 and ErbB3 are non-authonomous receptors: ErbB2does not bind to any known ligand, whereas ErbB3 has nokinase activity.
Under physiological conditions ErbB2 and ErbB3 signal only in thecontext of ligand-induced heterodimers
ErbB2/HER2: an atypical RTK
Sequence divergence in the extracellular region generatesa) inability to bind ligandb) extended conformation of the dimerization arm
ErbB2 is the hierarchically dominant ErbB receptor in dimer assembly
ErbB2 is refractory to endocytosis/downregulation
EGFR:ErbB2 heterodimers gain signalling potency due to decelerated ligand off-rates and refractoriness to endocytosis/downregulation
ErbB2 is a powerful signal amplifier
Strength and duration of signals generated by ErbB RTKs depend on the nature of the ligand:dimer combination
Oncogenic conversion of EGFR and ERBB2 in human tumours: mechanisms and therapeutic opportunities
Oncogenic conversion is caused by genetic lesions, which drive the constitutive signalling activity of EGFR and ERBB2.
Oncogenic signalling by EGFR and ERBB2 differs in quantitative and qualitative terms from physiological signalling.
This may create a state of “oncogene addiction” and cause tumour cells to become exquisitively sensitive to drugs that target EGFR and/or ERBB2.
Inactive wtEGFR L858R EGFR mutant
EGFR mutations in lung cancer generate constitutively active kinases
Yun, C-H et al., 2007, Cancer Cell, 11:217-227
Mutations cause constitutive activation of the EGFR kinase
Mutations are associated to EGFR copy gain
Mutations render EGFR refractory to down-regulation
Mutations sensitize tumour cells to EGFR kinase inhibitors
Compound effects of mutational activation of EGFR in NSCLC
ERBB2 is activated by gene amplification and attendant over-expression – mutational activation is very rare
Case study: breast cancer, ERBB2 subtype
ERBB2 overexpression drives constitutive homo-dimerization
ERBB2 over-expression is associated to increased ERBB3 expression, with ERBB3 being a necessary signalling subunitof ERBB2
RTKs are bistable systems, i.e. they transit from an “off” to an
“on” state with no intermediate states
Intramolecular interactions lock receptors in an inactive conformation, which is released upon ligand binding MUTATIONS, OVEREXPRESSION
Restricted ligand availability limits receptor activation AUTOCRINE PRODUCTION of LIGANDS
Feedback inhibition restricts receptor activityREFRACTORINESS to DOWN-REGULATION (severalmechanisms)
Oncogenic conversion of EGFR and ERBB2 releases the receptors from these constrains, thus allowing unabated signalling activity
Signal promiscuity imposed by ERBB2
average: 7.2 average: 17
Jones, RB et al., 2006 Nature, 439:168-174
Over-expression modifies the quality of signals generated by EGFR and ERBB2
Jones, RB et al., 2006 Nature, 439:168-174
Genetic lesions of EGFR and ERBB2 in humantumours lead to constitutive signalling activity which differs from physiological signalling in quantitative and qualitative terms
Cetuximab inhibits ligand-dependent activation of EGFR
Yun, C-H et al., 2007, Cancer Cell, 11:217-227
Mutations in the EGFR kinase may increase its affinity for competitive ATP inhibitors such as Gefitinib
Different mutations may display different sensitivity to competitive ATP inhibitors: shall drugs get personal?
Targeting the ErbB network, rather than any individual ErbB RTK may result in a therapeutic advantage
Citri et al. Nature Reviews Molecular Cell Biology 7, 505–516 (July 2006)
Conclusions
Oncogenic signalling by EGFR and ErbB2 originates from thesubversion of key regulatory principles of receptor activation
Oncogenic conversion grants EGFR and ErbB2 full operationalautonomy as well as evasion from negative regulation
Targeting EGFR and ErbB2 in tumours must take into accountthe “design principles” of oncogenic signalling by EGFR and ErbB2, including aberrant network activation